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Abstract 
 
Background 
Delirium incidence, duration and severity in patients admitted to the intensive care unit (ICU) 
due to COVID-19 is not known.  
Methods 
We conducted an observational study at two large urban academic Level 1 trauma centers. 
Consecutive patients admitted to the ICU with a positive SARS-CoV-2 nasopharyngeal swab 
polymerase chain reaction test from March 1st, 2020 to April 27, 2020 were included. Individuals 
younger than 18 years of age, without any documented delirium assessments (CAM-ICU), or 
without a discharge disposition were excluded. The primary outcomes were delirium rates and 
delirium duration and the secondary outcome was delirium severity. Outcomes were assessed 
for up to the first 14 days of ICU stay.  
Results 
Of 243 consecutive patients with confirmed COVID-19 admitted to the ICU, 144 met eligibility 
criteria and were included in the analysis. Delirium occurred in 73.6% (106/144) and delirium or 
coma occurred in 76.4% (110/144). Sixty-three percent of patients were positive for delirium on 
the first CAM-ICU assessment. The median duration of delirium and coma was 7 days (IQR: 3-
10), and the median delirium duration was 5 days (IQR: 2-7). The median CAM-ICU-7 score 
was 6 (IQR: 4-7) representing severe delirium. Mechanical ventilation was associated with 
greater odds of developing delirium (OR: 42.1, 95%CI: 13.0-137.1). Mortality was 26.4% in 
patients with delirium compared to 15.8% in patients without delirium. 
Conclusions 
73.6% of patients admitted to the ICU with COVID-19 experience delirium that persists for 
approximately 1 week. Invasive mechanical ventilation is significantly associated with odds of 
delirium. Clinical attention to prevent and manage delirium and reduce delirium duration and 
severity is urgently needed for patients with COVID-19.  
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Introduction 
 The Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) novel coronavirus (COVID-
19) has emerged as a global pandemic and is associated with rapid spread, severe respiratory 
failure and significant morbidity and mortality.1,2 As clinical experience with COVID-19 grows, 
neurologic manifestations of the disease are receiving increased attention. A recently published 
small case series from France reported delirium occurred in 26/40 (65%) of patients admitted to 
the intensive care unit with COVID-19.3 However, the duration and severity of delirium in 
critically ill COVID-19 patients have not been well described.   
Delirium is a serious neurologic syndrome independently associated with longer duration 
of mechanical ventilation, prolonged ICU and hospital stays, increased mortality, and 
institutionalization after discharge.4-8 Increasing levels of delirium severity and duration amplify 
these outcomes, and are independently associated with worsening cognitive and functional 
outcomes post discharge.9-12 Prior to COVID-19, the prevalence of delirium in mechanically 
ventilated patients has been decreasing from a historically high rate of 80% to a range of 16.5-
33%.13-19 In the setting of the current global health crisis, hospital resources have been 
stretched to their limits to meet the needs of a large number of critically ill patients. The 
unintended impact of limited resources on clinical practice has raised concerns that current ICU 
delirium rates have returned to the historically high levels.20-22 As of May 23, 2020, there are 
1.64 million confirmed COVID-19 cases in the US and approximately 12% of COVID-19 patients 
required intensive care unit (ICU) level care.1,2,23  In this context, delirium is likely to pose a long-
term public health challenge if rates in the United States are as high as recently reported in 
France.  
 Therefore, we conducted this study at two large academic health systems in urban 
Midwest to measure incidence of delirium, delirium duration and delirium severity, and 
investigate risk factors associated with delirium in critically ill patients admitted with COVID-19.  
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Methods  
The observational study was conducted at two large, urban, academic, Level 1 trauma 
centers (Indiana University Health Methodist Hospital and Eskenazi health) serving as major 
referral hospitals for the state of Indiana and affiliated with Indiana University School of 
Medicine (Indianapolis, Indiana). Methodist Hospital is an 802-bed quaternary care referral 
center with an average of 150 ICU admissions per month. Eskenazi Health is a 336-bed safety 
net hospital with an average of 120 ICU admissions per month. The study received ethical 
approval from the Institutional Review Board at Indiana University. All consecutive patients 
admitted to the intensive care units of Methodist Hospital and Eskenazi Health with a positive 
result by SARS-CoV-2 nasopharyngeal swab polymerase chain reaction test from March 1, 
2020 to April 27, 2020 were included. Exclusion criteria were: patients under the age of 18, 
admitted after April 27, 2020, patients with no delirium assessments recorded in the electronic 
medical record for the duration of the follow up period, and those still admitted to the ICU or 
hospital at the end of the study period. We excluded patients remaining admitted to the ICU or 
hospital to accurately identify delirium duration and to prevent confounding of downstream 
effects of delirium on mortality and length of stay. Clinical outcomes were followed up until April 
29, 2020 (date inclusive) or until the patient transferred out of the ICU. 
 
Exposures and Outcomes  
The main exposure variables were patients’ demographics, comorbidities, laboratory 
results and severity of illness at admission. The primary outcomes were rate of delirium and 
delirium/coma duration during the first 14 days of admission to the ICU. Delirium/coma duration 
was defined by the number of days the patient was alive and had documented delirium or coma, 
representing duration of abnormal cognitive status. Patients who were discharged from the 
intensive care unit prior to 14 days did not have subsequent delirium or coma assessments 
performed outside the ICU. Coma was assessed using the Richmond Agitation Sedation Scale 
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(RASS) and delirium was identified through the Confusion Assessment Method for the ICU 
(CAM-ICU). Coma was defined as a RASS score of -4 or -5, making patients ineligible for a 
CAM-ICU screening, while patients with a RASS score of -3 or greater were eligible for a CAM-
ICU assessment.24,25 The CAM-ICU score was determined by examining the patient for (a) 
acute or fluctuating changes in mental status, (b) inattention, (c) altered level of consciousness, 
and (d) disorganized thinking. Patients were considered delirious if they displayed (a) and (b), 
plus (c) and/or (d) on the CAM-ICU. ICU nurses administered the RASS and CAM-ICU twice 
daily (around 0700 to 0800, and then between 1900 to 2000) to measure level of consciousness 
and delirium, respectively. These standardized and validated screening tools were implemented 
in our healthcare systems in 2011 and are normally obtained throughout the ICU stay. 
Hyperactive delirium was defined as a RASS score of +1 to +4 at the time of positive CAM-ICU, 
and hypoactive delirium was defined as a RASS score -3 to 0 with a positive CAM-ICU score. 
The secondary outcome of delirium severity was assessed using the Confusion Assessment 
Method for the Intensive Care Unit-7 (CAM-ICU-7) which requires all components of the CAM-
ICU to be assessed for each patient rather than a dichotomous CAM-ICU positive or negative 
result. The CAM-ICU-7 was implemented into the electronic medical record at Eskenazi Health 
in 2017, and is assessed twice daily in the subset of patients receiving care at this hospital site. 
CAM-ICU-7 scores range from 0 to 7, with 0-2 indicating no delirium, 3-5 mild to moderate 
delirium, and 6-7 as severe delirium.12 
 
Data Collection 
Research assistants familiar with electronic medical systems at the hospitals (Cerner 
PowerChart, Epic Health Systems) abstracted study data from the medical record, including 
CAM-ICU assessments performed by clinical nurses, and results were entered directly into an 
electronic REDCap database. Data obtained from the medical record included patient 
demographics (age, gender, self-reported race), insurance status, comorbidities, vital signs, 
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laboratory and imaging results (within 24 hours of ICU admission), level of consciousness 
(RASS), date/time and results of delirium assessments for up to the first 14 days of ICU stay 
(overall CAM-ICU positive or negative, including CAM-ICU features as applicable: altered 
mental status, disorganized thinking, altered level of consciousness, disorganized thinking; and 
CAM-ICU-7 scores), SARS-CoV-2 test results, and dates of admission and discharge from 
hospital and ICU. Date of death during the hospitalization was also recorded including level of 
care at time of death (ICU vs. non-ICU). Comorbidities are presented as Charlson Comorbidity 
Index using diagnoses lists documented in the medical record. Acute Physiology and Chronic 
Health Evaluation Score (APACHE-II) was calculated using laboratory values, vital signs, and 
neurologic assessments from first 24 hours of ICU admission.  
 
Statistical Analysis 
Demographic and clinical characteristics were compared between patients who had 
delirium positive and those without delirium using two-sample t-tests (normal data) and 
Wilcoxon Rank Sum tests (skewed data) for continuous outcomes or Fisher’s Exact test for 
categorical variables. Summary statistics including median and inter-quartile range (IQR) were 
provided for patients with delirium. Logistic regression was used including demographic or 
clinical characteristics that were significantly different between patients with delirium and those 
without delirium as independent variables to identify factors associated with delirium.  
 
Results 
Two-hundred forty-three consecutive patients with COVID-19 were admitted from March 
1, 2020 to April 27, 2020 to the ICUs at two hospital systems. We excluded 99 patients; 21 did 
not have any delirium assessments, and 78 remained admitted at the end of the follow up 
period (see Supplementary Figure 1). In total, 144 patients comprised the study cohort. 
Demographics and clinical characteristics for the cohort are presented in Table 1. The mean 
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age of the cohort was 58 years (SD=15.8), 42.4% were female, 50% African American and 
14.1% Hispanic, 32.6% utilized commercial insurance, and 21.5% Medicare. The median 
Charlson Comorbidity Index score was 1 (IQR: 0-2), with hypertension (59.7%), obesity 
(56.1%), tobacco use (27.1%), and chronic lung disease (26.4%) the most frequent comorbid 
conditions. The median APACHE-II score was 17 (IQR: 13-24), and 73% of patients in the 
cohort underwent invasive mechanical ventilation. Cerebrovascular accident (ischemic or 
hemorrhagic) was identified in 1.4% (2/144) of patients.  
 
Delirium and Coma in Critically Ill Patients with COVID-19 
Delirium occurred in 73.6% (106/144) of patients in the study, whereas delirium or coma 
occurred in 76.4% (110/144). Forty-four percent of patients experienced coma. Of patients with 
delirium, 63.2% were positive on the first CAM-ICU assessment, and 36.8% developed delirium 
on a subsequent CAM-ICU screening. As shown in Table 1, patients with delirium had higher 
median APACHE-II severity of illness scores (19, IQR: 15-26 vs. 13.5, IQR: 9-17, p<0.001) and 
were more likely to be mechanically ventilated (91.5% vs. 21.1%, p<0.001). Patients with 
delirium had lower PaO2:FiO2 ratios (90, IQR:70.0-140.0 vs. 134.4, IQR: 95.0-188.9, p=0.016) 
and lower Glasgow Coma Scale scores (10.0, IQR: 6.0-14.0 vs. 15.0, IQR: 14-15.0, p<0.001) 
during the first 24 hours of ICU admission compared to those without delirium. Patients with 
delirium also had decreased level of consciousness by RASS score (-1.6, IQR:-2.5, -0.8 vs. 0, 
IQR:0-0) compared to patients who did not develop delirium assessed over 14 days of ICU stay.   
 
Delirium Duration, Subtypes of Delirium and Delirium Severity 
The median duration of delirium and coma was 7 days (IQR: 3-10) (see Table 2), and 
median delirium duration was 5 days (IQR: 2-7). Patients had a median RASS of -2 (IQR: -3,0) 
at the time of ICU admission indicating light sedation. Figure 1 shows the daily rates of patient’s 
delirium, coma or delirium/coma-free status for up to 14 days of ICU admission. In our study 
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cohort, hypoactive delirium occurred in 86.8% of patients on the first CAM-ICU assessment, and 
the median duration of hypoactive delirium was 4 days (IQR: 2-4). Details of the subtypes of 
delirium are shown in Table 2 and Figure 2. In the subset of patients with delirium severity 
assessments (n=73), the median CAM-ICU-7 score was 6 (IQR: 4-7) representing severe 
delirium.  
 
Factors Associated with Delirium 
Patients with delirium had greater mechanical ventilation days (median 8.7 days, IQR: 
4.5-12.9 vs. 0, IQR: 0-0, p<0.001) and ICU days (median 11.0, IQR: 6.9-15.2 vs. 3.6, IQR: 1.7-
6.0, p<0.001) compared to patients without delirium (Table 3). We did not find a significant 
difference in hospital mortality between COVID-19 patients with delirium and those without 
(26.4% vs. 15.8%, p=0.27), as shown in Table 3. Daily rates of patient’s discharge from ICU and 
death over the first 14 days are shown in Supplementary Figure 2. In the logistic regression 
model consisting of age, receipt of mechanical ventilation, and APACHE-II scores, only 
mechanical ventilation was significantly associated with greater odds of developing delirium 
(OR: 42.1, 95% CI: 13.0-137.1, p<0.001).  
 
Discussion 
In this observational study of COVID-19 patients admitted to the ICU at 2 large hospitals, 
74% of patients experienced delirium, delirium occurred early in the ICU course (within the first 
two days), and the abnormal cognitive states of delirium or coma persisted for median length of 
one week. In addition, patients with COVID-19 experienced severe delirium, and invasive 
mechanical ventilation was associated with a marked increase in odds of delirium. While 
mortality rates did not statistically differ by delirium status likely due to the small sample size of 
patients without delirium, we found mortality to be 10% higher in patients with delirium. To the 
best of our knowledge, our study is the first to describe delirium rates, duration and severity in 
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critically ill patients with COVID-19 using standardized delirium assessment tools. Due to the 
increased risk of mortality and morbidity following delirium, including the development of long-
term cognitive impairment and post intensive care syndrome, this study has important 
implications for clinical practice, the recovery of patients with COVID-19 admitted to intensive 
care, public health decision making, and even future research priorities.26,27  
Our study findings represent a significant departure from recently reported trends in 
rates of ICU delirium, including rates of mechanical ventilation (36%), delirium (22.7%), and 
coma (24.0%) at our own center during the influenza pandemic occurring in 2009-2010 (see 
Supplementary Table 2). Reductions in the prevalence of ICU delirium from a historical high of 
80% to rates of 16.5-33% have been reported over the past two years.13,16,17,19 These reductions 
were likely linked to the implementation of the Society of Critical Care Medicine’s PADIS 
guidelines, multi-disciplinary bundled protocols for delirium prevention (ABCDEF), avoidance of 
deliriogenic agents, increasing use of non-invasive ventilation strategies and heated high-flow 
nasal cannula devices leading to reduced rates of invasive ventilation, and increasing clinician 
awareness regarding the harms of delirium.17,28-30 The COVID-19 crisis has seriously challenged 
these care improvements as pre-established multi-disciplinary care models of ICU care become 
disrupted and health systems are overwhelmed with critically ill patients requiring invasive 
mechanical ventilation. In addition, it has been proposed that COVID-19 may directly infiltrate 
the central nervous system leading to delirium.31-33 A recent meta-analysis on neuropsychiatric 
symptoms associated with severe coronavirus infections concluded that signs of delirium 
(confusion 27.9% 95% CI: 20.5-36.0, impaired concentration or attention 38.2% 95% CI: 29.0-
47.9, and altered consciousness 20.7% 95% CI: 12.6-30.3) were common in Severe Acute 
Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).34 Further, as 
recent studies have reported neurologic symptoms such as anosmia in COVID-19 and SARS-
CoV-2 has been identified in cerebrospinal fluid as well as brain tissue, the neurotoxic impact of 
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COVID-19 is increasingly plausible.31-33,35  The possible pathways for neuronal damage due to 
COVID-19 require additional study.  
While effective pharmacological therapies for treatment of COVID-19 as well as delirium 
are not yet available, our study sheds light on an alarming burden of delirium and coma in 
patients admitted to the ICU and the need for continued efforts on delirium prevention. Following 
and implementing evidence-based ICU practices (such as the ABCDEF bundle) to minimize 
delirium occurrence and severity under the pandemic conditions will likely remain an ongoing 
challenge.30 The continued use of screening tools for delirium and delirium severity can also 
provide bedside clinicians with dynamic assessments to measure the impact of interventions in 
real-time.9,12 As resources shrink in the face of the pandemic and the health care response 
disrupts, it is imperative to continue to follow and implement time-tested evidence-based 
practices. Finally, delirium in critically ill patients has been associated with long-term cognitive 
decline.10,36 If other studies confirm higher rates of delirium in COVID-19 ICU patients, 
longitudinal follow-up will be crucial to understand the full impact of COVID-19 and understand 
the pathophysiology of COVID-19 related delirium. 
Our study does have important limitations. This analysis is limited by its reliance on data 
from the medical record including clinician-administered delirium assessments. The limitation of 
clinician-administered delirium assessments has been minimized by the rigorous 
implementation and continued education on the CAM-ICU and CAM-ICU-7 at the participating 
institutions. Our analysis also does not include medication exposure data, adherence to the 
ABCDEF bundle at the patient level, education levels, baseline functional status, or baseline 
cognitive function and therefore we are unable to fully explain the rates of delirium seen in our 
study. Our analysis is also limited to delirium and coma assessments performed in the first 
fourteen days of ICU stay, and therefore we are unable to describe the trajectory of delirium and 
coma for the duration of the hospitalization in this report. Strengths of the study include 
incorporation of delirium severity data, a racially and socioeconomically diverse cohort of 
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patients and protocolized delirium assessments conducted by bedside clinicians at two high 
volume and high acuity centers.  
 
Conclusion 
We found that in contrast to recent rates of delirium in ICU patients, 74% of patients with 
COVID-19 develop delirium which persists for approximately 1 week, and occurs at high 
severity. Invasive mechanical ventilation is significantly associated with delirium development. 
Given these findings, continued attention to prevent and manage delirium is critical. 
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Table 1. Characteristics of Critically Ill Patients Admitted with COVID-19 (n=144) 
 
Demographic/Clinical 
Characteristic 
Total 
(n=144) 
Delirium Positive 
(n=106) 
Delirium Negative 
(n=38) 
Age, mean (SD) 58.0 (15.8) 58.9 (15.5) 55.7 (16.5) 
Age, stratified n (%)    
18-49, n (%) 44 (30.6) 31 (29.2) 13 (34.2) 
50-64, n (%) 48 (33.3) 32 (30.2) 16 (42.1) 
65+, n (%) 52 (36.1) 43 (40.6) 9 (23.7) 
Sex, n (%)    
Female 61 (42.4) 48 (45.3) 13 (34.2) 
Race, n (%) 
African American 71 (50.0) 50 (48.1) 21 (55.3) 
Caucasian  43 (30.3) 32 (30.8) 11 (28.9) 
Hispanic 20 (14.1) 15 (14.4) 5 (13.2) 
Insurance, n (%) 
Medicare 31 (21.5) 22 (20.8) 9 (23.7) 
Medicaid 19 (13.2) 15 (14.2) 4 (10.5) 
Medicare & Medicaid 15 (10.4) 11 (10.4) 4 (10.5) 
Commercial 47 (32.6) 33 (31.1) 14 (36.8) 
Self-pay 17 (11.8) 13 (12.3) 4 (10.5) 
Comorbidities, n (%)    
Hypertension 86 (59.7) 66 (62.3) 20 (52.6) 
Diabetes 58 (40.3) 41 (38.7) 17 (44.7) 
Obesity, BMI >30 74 (56.1) 59 (60.2) 15 (44.1) 
Tobacco use 39 (27.1) 27 (25.5) 12 (31.6) 
COPD or Asthma 38 (26.4) 29 (27.4) 9 (23.7) 
Chronic kidney disease 22 (15.3) 17 (16.0) 5 (13.2) 
Chronic Heart Failure 18 (12.5) 14 (13.2) 4 (10.5) 
Cardiac Artery Disease 17 (11.8) 15 (14.2) 2 (5.3) 
Dementia 5 (3.5) 4 (3.8) 1 (2.6) 
Charlson Comorbid Index 1 (0-2) 1 (0-2) 1 (0-2) 
APACHE II * 17 (13-24) 19 (15-26) 13.5 (9-17) 
Laboratory Values, Clinical and Respiratory Characteristics, median (IQR) 
White blood cell count x109/L 8.7 (6.5-12.6) 8.8 (6.5-13.6) 7.5 (6.5-9.9) 
Glasgow Coma Scale (0-15) 10.0 (7.0-15.0) 10.0 (6.0-14.0) 15.0 (14.0-15.0) 
Partial Pressure of Oxygen 
(PaO2) mmHg 
73.0 (59.0-105.0) 73.0 (61.0-106.0) 74.5 (53.0-95.0) 
PaO2:FiO2 ratio* 96.7 (73.8-150.0) 90.0 (70.0-140.0) 134.4 (95.0-188.9) 
RASS (14 days) -1, (-2, 0) -1.6 (-2.5, -0.8) 0 (0, 0) 
Invasive mechanical 
ventilation* 
105 (72.9) 97 (91.5) 8 (21.1) 
Presence of Shock 21 (14.6) 19 (18.1) 2 (5.1) 
    
Table 1 describes the demographic and clinical characteristics of the overall cohort. Laboratory values, clinical, 
respiratory characteristics, and severity of illness measurements represent data from first 24-hours of ICU 
admission. Delirium status determined by a positive CAM-ICU clinical assessment. RASS scores were 
calculated using scores for up to 14 days. Severity of illness, Glasgow Coma Scale, RASS scores, percent 
mechanically ventilated, and PaO2:FiO2 were significantly different between groups (no delirium/delirium) in 
univariate analysis.  
*significant difference between groups, p<.05 
 
Abbreviations: APACHE=Acute Physiology and Chronic Health Evaluation, BMI=Body Mass Index (calculated 
with height and weight at admission), CKD=Chronic Kidney Disease includes End Stage Renal Disease, 
COPD=Chronic Obstructive Pulmonary Disease, ICU=Intensive Care Unit, SD=Standard Deviation 
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Table 2 – Clinical outcomes in Critically Ill Patients Admitted with COVID19 Who Developed Delirium 
 
Outcome Measures Patients with Delirium 
(n=106) 
Duration of Delirium and Coma, median (IQR) 
Delirium/coma days 7 (3-10) 
Delirium duration in days 5 (2-7) 
Coma duration in days 1 (0-4) 
  
Subtypes of Delirium, n (%)   
Hypoactive delirium at 1st ICU assessment 92 (86.8) 
Hyperactive delirium at 1st ICU assessment 14 (13.2) 
 
Duration of Subtypes of Delirium, median days (IQR)  
Hypoactive delirium duration days 4 (2-6) 
Hyperactive delirium duration days 0 (0-1) 
 
Delirium Severity, median (IQR) 
CAM-ICU-7 score 
 
6 (4-7) 
 
Delirium was defined as a positive CAM-ICU assessment in the patient medical record for up to 14 days 
during their ICU COVID-19 stay. Coma was defined by Richmond Agitation Sedation Score of -4 or -5. 
Duration of delirium was defined as number of days patient was CAM-ICU positive on either morning or 
afternoon assessment for up to 14 days while admitted to the ICU. Duration of coma was defined as 
number of days patient had coma by RASS score on either morning or afternoon assessment for up to 14 
days of ICU stay. Hypoactive delirium was defined by (RASS) of -1 to -3 with positive CAM-ICU, 
Hyperactive delirium was defined by a RASS score of +1 to +3 with positive CAM-ICU. Delirium severity 
was measured using the CAM-ICU-7 in 73 patients (0-7, 0-2: no delirium; 3-5: mild to moderate delirium; 6-
7: severe delirium). 
 
Abbreviations: CAM-ICU and CAM-ICU-7=Confusion Assessment Method-Intensive Care Unit, 
ICU=Intensive Care Unit, IQR=Interquartile Range, RASS= Richmond Agitation and Sedation Scale 
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Table 3 – Clinical outcomes of patients with COVID-19 in the Intensive Care Unit 
Clinical Outcomes Total 
(n=144) 
Delirium 
Positive 
(n=106) 
Delirium 
Negative 
(n=38) 
p-value 
Median (IQR), Days 
Mechanical ventilation  6.2 (0-11.3) 8.7 (4.5-12.9) 0 (0-0) <.001 
ICU LOS 9.7 (4.7-14.7) 11.0 (6.9-15.2) 3.6 (1.7-6.0) <.001 
Hospital LOS 30.5 (23-34) 31 (25-35) 26.5 (20-32) .020 
     
Mortality, n (%)     
In-hospital 34 (23.6) 28 (26.4) 6 (15.8) .265 
Table 3 describes the clinical outcomes in COVID-19 patients admitted to the ICU. The overall cohort is 
described then divided by delirium status (positive CAM-ICU). Univariate testing was completed to investigate 
statistical significance.  
 
Abbreviations: ICU=Intensive Care Unit, IQR=Interquartile Range, LOS=Length of Stay 
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Figure 1. Daily Rates of Delirium, Coma, or Without Delirium/coma Status as Assessed up to 
First 14 Days of Intensive Care Unit Stay (n=144)  
 
 
 
 
Daily percentages do not equal 100% due to incomplete assessments, death, or discharge from intensive care unit. 
Delirium was defined as a positive CAM-ICU assessment on either morning or afternoon assessment. Coma was 
defined by Richmond Agitation Sedation Score of -4 or -5. Without delirium or coma was defined by RASS greater 
than -4 and a negative CAM-ICU on either morning or afternoon assessment.   
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Figure 2. Subtypes of Delirium in Critically Ill Patients with COVID-19 Who Developed Delirium 
(n=106) 
 
 
 
 
 
CAM-ICU and RASS assessments were performed up to twice daily while patient was admitted to the intensive care 
unit. Hypoactive delirium was defined by Richmond Agitation Sedation Scale (RASS) of -1 to -3 with positive CAM-
ICU, Hyperactive delirium was defined by a RASS score of +1 to +3 with positive CAM-ICU. Mixed delirium: patients 
with both hyperactive and hypoactive delirium assessment on a given ICU day.  
 
Abbreviations: CAM-ICU=Confusion Assessment Method-Intensive Care Unit, RASS= Richmond Agitation and 
Sedation Scale 
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